The call, on record
HIMS bullish call
Quoted text as recorded“This is like I said the biggest holding in the asymmetric portfolio.”@ 9:57 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Jul 23, 2026
- Timeframe
- Current holding; no explicit investment endpoint.
- Interpreted confidence
- medium
- Specificity
- vague
Email me when HIMS calls resolve
When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
Strongly BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
Hoium remains constructive on his largest holding as Hims & Hers expands its specialties, international footprint and data-driven treatment platform. He considers the valuation compelling if growth returns and presents a conditional scenario for a much higher enterprise-value-to-sales multiple.
Key arguments
- Peptide availability could attract subscribers and expand the platform's treatment options.
- Labs, integrated health data and personalized treatments could reinforce customer engagement and platform value.
- Eucalyptus expands the company's reach into Australia and Japan.
- Subscriber growth may continue recovering, while higher-priced branded weight-loss treatments could raise revenue per subscriber.
- An enterprise-value-to-sales multiple of 3.4 leaves substantial potential for valuation expansion if growth accelerates.
Counter-arguments acknowledged
- Revenue growth has slowed and margins have moved in the wrong direction.
- GLP-1 compounding restrictions created difficult comparisons and pressured subscriber economics.
- Peptide regulatory recommendations still require further action before products can launch.
- Low-priced peptide treatments may contribute less revenue per customer than weight-loss treatments.
Hedges and caveats (from the video)
- FDA panel recommendations do not authorize immediate peptide compounding; product launches may wait until 2027.
- Revenue growth has decelerated and margins have deteriorated.
- Changes to GLP-1 compounding affected subscriber growth and revenue per subscriber.
- Peptides are an incremental improvement rather than a game changer and may carry low monthly prices.
- The valuation expansion scenario depends on growth reaching 50% or more over the next year or two.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Jul 23, 2026, 8:07 PM UTC
- First recorded by TubeRank
- Nov 1, 2026, 4:13 AM UTC
- Record last updated
- Nov 1, 2026, 4:13 AM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Nov 1, 2026, 4:13 AM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Not recorded
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
No explanation was recorded for this outcome.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
The surrounding discussion endorses retaining the largest holding through an attractive valuation and anticipated improvement, but provides no explicit new purchase commitment.